Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benalotide GLP-1 receptor agonist in type 2 diabetes mellitus with abdominal obesity
ChiCTR2200061003Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital Affiliated to Fudan University Qingpu Branch
- Start
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of benalotide in type 2 diabetes mellitus (T2DM) and Abdominal adiposity (ABCD) (2 arms), sponsored by Zhongshan Hospital Affiliated to Fudan University Qingpu Branch. Primary endpoint: Subcutaneous fat content. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
benalotide
03
Conditions
type 2 diabetes mellitus (T2DM)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on ChiCTR2200061003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061003.